In elderly patients with suspected prostate cancer, PSMA PET/CT can diagnose advanced disease and aid in therapy selection without the need for a biopsy. Published in the July issue of The Journal of ...

One-third of patients with PSA levels below 0.2 ng/mL after radical prostatectomy have recurrent disease identifiable by PSMA PET. More than one-third of patients with PSA levels less than 0.5 ng/mL ...

A PSMA PET scan found more recurrent prostate cancer at low PSA levels than a standard scan, helping guide more potentially curative treatment decisions. A newer type of prostate cancer scan called 64 ...

A phase 3 trial found that PSMA PET-CT after equivocal MRI halves the prostate biopsy rate in men at high clinical risk for prostate cancer. In men with high clinical risk and equivocal prostate ...

Interaction of age and benefit of treatment intensification in advanced prostate cancer: An aggregate meta-analysis of 14 randomized trials. Effect of concomitant medications on treatment response and ...

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found. Findings ...

Natural killer cell activity in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. This is an ASCO Meeting Abstract from the 2023 ASCO Genitourinary Cancers ...

Gozetotide is a drug for diagnostic application in adults with prostate cancer. It is currently the only diagnostic agent that recognizes PSMA-positive prostate cancer and can therefore identify ...

Telix Pharmaceuticals (NASDAQ:TLX) hosted an educational webinar outlining its next-generation prostate-specific membrane ...

BOSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class comprehensive epigenomic liquid biopsy platform, ...